The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $37.21 in the prior trading day, Hims & Hers Health Inc (NYSE: HIMS) closed at $36.25, down -2.58%. In other words, the price has decreased by -$2.58 from its previous closing price. On the day, 11.16 million shares were traded. HIMS stock price reached its highest trading level at $38.0299 during the session, while it also had its lowest trading level at $35.68.
Ratios:
Our goal is to gain a better understanding of HIMS by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.10 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 71.09. For the most recent quarter (mrq), Quick Ratio is recorded 1.64 and its Current Ratio is at 1.88. In the meantime, Its Debt-to-Equity ratio is 1.92 whereas as Long-Term Debt/Eq ratio is at 1.92.
Upgrades & Downgrades
In the most recent recommendation for this company, Barclays on December 09, 2025, initiated with a Overweight rating and assigned the stock a target price of $48.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 09 ’25 when Perez Garcia Andrea G sold 2,500 shares for $39.17 per share. The transaction valued at 97,925 led to the insider holds 80,166 shares of the business.
Perez Garcia Andrea G bought 2,500 shares of HIMS for $97,925 on Dec 09 ’25. On Nov 24 ’25, another insider, Boughton Soleil, who serves as the Chief Legal Officer of the company, sold 2,631 shares for $35.22 each. As a result, the insider received 92,664 and left with 153,225 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HIMS now has a Market Capitalization of 8252258304 and an Enterprise Value of 8740537344. As of this moment, Hims’s Price-to-Earnings (P/E) ratio for their current fiscal year is 67.02, and their Forward P/E ratio for the next fiscal year is 60.59. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.95. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.73 while its Price-to-Book (P/B) ratio in mrq is 14.19. Its current Enterprise Value per Revenue stands at 3.953 whereas that against EBITDA is 51.871.
Stock Price History:
The Beta on a monthly basis for HIMS is 2.36, which has changed by 0.19569409 over the last 52 weeks, in comparison to a change of 0.12838376 over the same period for the S&P500. Over the past 52 weeks, HIMS has reached a high of $72.98, while it has fallen to a 52-week low of $23.97. The 50-Day Moving Average of the stock is -17.39%, while the 200-Day Moving Average is calculated to be -20.93%.
Shares Statistics:
The stock has traded on average 25.91M shares per day over the past 3-months and 14280720 shares per day over the last 10 days, according to various share statistics. A total of 219.12M shares are outstanding, with a floating share count of 204.68M. Insiders hold about 10.09% of the company’s shares, while institutions hold 89.50% stake in the company. Shares short for HIMS as of 1764288000 were 67327436 with a Short Ratio of 2.60, compared to 1761868800 on 70158018. Therefore, it implies a Short% of Shares Outstanding of 67327436 and a Short% of Float of 36.580002.
Earnings Estimates
Hims & Hers Health Inc (HIMS) is currently under the scrutiny of 11.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $0.15, with high estimates of $0.3 and low estimates of $0.1.
Analysts are recommending an EPS of between $0.58 and $0.38 for the fiscal current year, implying an average EPS of $0.48. EPS for the following year is $0.66, with 11.0 analysts recommending between $1.37 and $0.33.
Revenue Estimates
12 analysts predict $617.48M in revenue for. The current quarter. It ranges from a high estimate of $624.72M to a low estimate of $608.22M. As of. The current estimate, Hims & Hers Health Inc’s year-ago sales were $481.14MFor the next quarter, 12 analysts are estimating revenue of $658.67M. There is a high estimate of $673.8M for the next quarter, whereas the lowest estimate is $630.7M.
A total of 14 analysts have provided revenue estimates for HIMS’s current fiscal year. The highest revenue estimate was $2.35B, while the lowest revenue estimate was $2.33B, resulting in an average revenue estimate of $2.35B. In the same quarter a year ago, actual revenue was $1.48BBased on 13 analysts’ estimates, the company’s revenue will be $2.77B in the next fiscal year. The high estimate is $2.94B and the low estimate is $2.52B.
